on Viromed Medical AG (isin : DE000A3MQR65)
Viromed Medical AG Secures Funding for Cold Plasma Innovations
On March 23, 2026, Viromed Medical AG announced receiving funding approval from the Federal Ministry of Research, Technology and Space. The funding, granted under the Research Allowance Act, supports advances in cold plasma technology, with a total in the high six-figure euro range.
The financial boost will aid the development of critical medical systems like PulmoPlas®, a stationary system designed to inactivate germs in the respiratory tract for use in ventilation processes. A mobile device, ViroCap®, is also being developed, promoting wound healing through contact-free plasma application. These projects aim to tackle major medical challenges and push technological boundaries.
The funding highlights Viromed's innovative strength and confirms the relevance of its cutting-edge solutions in non-pharmacological treatments. With these developments, Viromed is set to enhance its standing in the medical technology sector.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Viromed Medical AG news